Celestica
NYSE · CLSInvestableEntry review due
$371.57
Oct 7, 2026-4.29%last session
Close
Oct 7, 2026
Entry rationale
At the dated reference price, the shares offer no margin of safety against our base or weighted scenario values. Price is the obstacle, not an established funding or execution blocker. A retreat into the model's buy range, or stronger evidence that durably improves the earnings outlook, would change the judgment.